TaiGen Biopharmaceuticals Holdings Ltd.

F*太景 (4157.TWO)

January, 2016
Safe Harbor Statement

This presentation is prepared by TaiGen Biopharmaceuticals Holdings Ltd. (“TaiGen”) and includes forward-looking statements about TaiGen and its business, including but not limited to statements regarding drug discovery, research and clinical development, regulatory approval processes, market opportunities and commercialization. These forward looking statements are subject to risks and uncertainties and may cause actual events or results to differ materially from our current expectations. Please refer to our prospectus for full disclosure of risks before making an investment decision. This presentation is copyright protected and cannot be reproduced without written permission from TaiGen.
A Research-Driven and Product Focus Company

- An approved product
- A high value pipeline
- A productive R&D platform
Company Highlights

- Founded in 2001 in Taipei and backed by blue-chip investors including MPM Capital and Taiwan National Development Fund
- Led by seasoned US-trained management team with pharma experience
- NCE pioneer in Greater China with an integrated R&D platform and proven track record
- Pipeline include first-in-class or best-in-class products to treat cancer or infectious disease
- First product, Taigexyn®, launched in Dec. 2015 and expected to get drug license in China in 2016
- Publicly listed in Taipei Exchange (TPEx) since Jan 2014
- Market capitalization of ~US$ 720M (as of 12/31/2015)
- Number of employees: 80; 75% in R&D with Masters, PhD, and MD degrees
## Seasoned Management Team
Each With 20+ Years in Related Fields

<table>
<thead>
<tr>
<th>Name / Title</th>
<th>Experiences</th>
</tr>
</thead>
</table>
| Ming-Chu Hsu, Ph.D.  
*Founder, Chairman, and CEO* | Director, Oncology and Virology Research, Roche |
| Richard King, Ph.D.  
*SVP Research* | Director, Discovery, AMRI  
Head, Discovery Chemistry, Hoechst Marion Roussel |
| Phillip Huang  
*Chief Commercial Officer in Asia* | Director China Marketing & Sales, Takeda |
| Peter Tsao, Ph.D.  
*VP Business Development* | Senior Director, Repros Therapeutics  
Director BD, Mitsubishi Tanabe, Tanabe Seiyaku |
| Edward Kuo, M.D.  
*VP Clinical Development* | Medical Director, Boehringer-Ingelheim, Pfizer, BMS |
| Angel Hsiao  
*Senior Director, Finance Department* | Project Manager, ShinZe Asset Management Servicing Co. (Consultant to Cerberus Group) |
Reputable Gov’t and Private Institutions Form a Strong Shareholders and BOD Bases

- 11 BOD members (3 independent Directors included) and 3 Supervisors

As of Jan. 9, 2016
TaiGen’s Focus is NCEs – The Highest Margins in the Value Curve

The Pharmaceutical Industry’s Value Curve

Over 300 Patents Granted for Global IP Protection

- Providing market exclusivity and out-licensing opportunities

<table>
<thead>
<tr>
<th>Product</th>
<th>Type of Patent</th>
<th>Patents Granted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nemonoxacin (Antibiotic)</td>
<td>Composition of Matter</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Salt Form</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Process</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Use</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Formulation</td>
<td>31</td>
</tr>
<tr>
<td>Burixafor (Stem Cell Mobilizer)</td>
<td>Composition of Matter / Use</td>
<td>75</td>
</tr>
<tr>
<td>Hepatitis C Virus Protease Inhibitor TG-2349 (HCV Protease Inhibitor)</td>
<td>Composition of Matter / Use</td>
<td>55</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>315</strong></td>
</tr>
</tbody>
</table>

As of Dec. 31, 2015
# Highly Differentiated NCEs in the Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Stages</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nemonoxacin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community Acquired Pneumonia (Oral)</td>
<td>Discovery Research</td>
<td>Taiwan IND</td>
</tr>
<tr>
<td>Community Acquired Pneumonia (I.V.)</td>
<td>Preclinical</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td>Community Acquired Pneumonia (Oral)</td>
<td>Phase I</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td>Community Acquired Pneumonia (I.V.)</td>
<td>Phase II</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td>Community Acquired Pneumonia /Diabetic Foot Infection (Oral)</td>
<td>Phase III</td>
<td>US IND</td>
</tr>
<tr>
<td><strong>Burixafor</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stem Cell Transplantation</td>
<td>NDA</td>
<td>US IND</td>
</tr>
<tr>
<td>Chemosensitization (Hematological Cancers)</td>
<td>Marked</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td>Stem Cell Transplantation</td>
<td>NDA</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td><strong>TG-2349 (Furaprevir)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Hepatitis C</td>
<td>Discovery Research</td>
<td>US IND / Taiwan</td>
</tr>
<tr>
<td>Chronic Hepatitis C</td>
<td>Preclinical</td>
<td>China IND (Category 1.1 New Drug)</td>
</tr>
<tr>
<td>***</td>
<td>Phase I</td>
<td>Application under review</td>
</tr>
</tbody>
</table>
Taigexyn® – NCE Antibiotic for Drug-resistant Infections

- Novel, non-fluorinated quinolone, broad-spectrum antibiotic with global IP protection until 2030
- Completed clinical development of oral formulation and filed NDA in Taiwan and China
- Launched in Taiwan in Dec. 2015 and expected to get drug license in China in 2016
- Completed two Phase 2 clinical trials in the US in CAP and DFI
- Received QIDP and Fast Track designations from US FDA
- Licensed to Zhejiang Medicine in China and R-Pharm in Russia
- Phase 3 trials of intravenous formulation in China has achieved the primary end point
- Conducting Phase 3 trials of intravenous formulation in Taiwan
- Continue to explore and expand partnerships in other territories
Taigexyn® – Key Message to Prescribers

**Potent**
• Superior activity against MRSA, VRSA, MDRSP, and PRSP

**Convenient**
• Once-daily use
• Oral and IV available

**Broad-spectrum**
• Excellent activity for Gram +ve, Gram -ve, and atypical pathogens

**Effective**
• Exceptional efficacy was shown in 3 CAP and 1 DFI trials

**Low resistance**
• Require mutations in three different bacterial genes

**Safe**
• Excellent safety profile
• No cardio-side effect
Burixafor – Next Generation Stem Cell Mobilizer and Chemsensitizer

- Potent and selective CXCR4 antagonist that mobilize stem cells and cancer cells from the bone marrow into peripheral circulation.

- Target indications:
  - Hematopoietic Stem Cell Transplantation (HSCT)
  - Chemosensitization

- Completed phase 1, and two Phase 2 studies in HSCT in US; a chemosensitization trial in AML patient under a CTA is ongoing

- Global IP protection including US, EU, Japan, China until 2028-2029
Burixafor – Simplify Collection/Banking of Hematopoietic Stem Cells for HSCT

- Current Standard of Care requires 5-8 days of G-CSF and an average of 4 leukapheresis sessions
- Burixafor monotherapy
  - Can be use alone in multiple myeloma patients to mobilize sufficient stem cells for hematopoietic stem transplantation
- Burixafor + G-CSF
  - Lower total cost of hematopoietic stem cell transplantation (US$100-150K)
  - Only two leukapheresis required
  - Reduce hospital stay
  - Reduce number of G-CSF injections and minimize bone pain

Source: EBMT
Metastatic Prostate Cancer Cells in the Bone Marrow

18F-Fluoride PET

Courtesy of Prof. K. Pienta


From J Clin Investigation 121:1298

Restricted & Confidential
## Burixafor – One Drug, Multiple Indications

<table>
<thead>
<tr>
<th>Autologous stem cell transplantation</th>
<th>Allogeneic stem cell transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed two POC trials in multiple myeloma, NHL, HD in the US.</td>
<td>Signed agreement with Cellex in Germany to initiate trials in allogeneic poor mobilizers. Potential to apply for orphan drug designation in US/EU.</td>
</tr>
<tr>
<td>Results suggest potential in reducing number of leukapheresis and hospital costs</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemosensitization in hematological malignancies</th>
<th>Chemosensitization in solid tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiated chemosensitization in acute myeloid leukemia at the Hematological Institute in Tianjin</td>
<td>Signed agreement with Johns Hopkins University Hospital for a pilot study in metastatic prostate cancer</td>
</tr>
</tbody>
</table>
Burixafor – Other Potential Indications

- Studies were performed in myocardial infarction model using mini-pigs
- Results showed that endothelial progenitors cell are being mobilized after administration of burixafor
- Significant improvement in LVEF (left ventricular ejection fraction) compared to the control group was observed
- Seeking partnerships to fully explore the potential
Burixafor – Milestones in the Next 12-24 Months

- Completed TG-0054-04 trials (n=12) in Q4 ‘15. Top-line data presented at the annual meeting of America Society of Hematology 12/5-8 Orlando, FL
- TaiGen will discuss with US FDA in February on advancing burixafor into the next phase of development
- Allogeneic HSCT in poor mobilizers – IIT plan to start end of Q1 ’16 at Cellex and Dresden University Hospital. Top-line data in cell mobilization expected in the next 12-18 months.
- Chemosensitization in refractory and relapsed AML – Phase 1/2 study started in China in May 2015
- Chemosensitization in metastatic prostate cancer – IIT initiated at Johns Hopkins University. Top-line data in cell mobilization kinetics and biomarkers expected in the next 18-24 months.
Furaprevir – Highly Effective and Affordable HCV Treatment

- Furaprevir is active against all six genotypes of HCV and has the potential to reduce total treatment duration to 12 weeks or less
- Phase 1/2a study was completed under IND with US FDA and results were presented at AASLD (late-breaking news).
- A Phase 2 12-week study of furaprevir in combination with peg-interferon and ribavirin in GT-1b patient is ongoing in Taiwan
- The data to date indicated that HCV RNA levels is undetectable as early as Week 1 after treatment and continue to be undetectable at Week 16 (SVR12)
- Clinical trial authorization (Class 1.1) was submitted to China FDA at the end of April 2015
- The high pricing of the DAA treatments make it out of reach for patients even in well-developed countries. The medical need in many middle income countries with high HCV burden such as China, Taiwan is still extremely high.
TaiGen’s Near-Term Goals and Long-Term Vision

- Launch and expand indications of Taigeyxn® in China and Taiwan
- Establish Taigeyxn® partnerships in other territories
- Advance Burixafor into the next phase of clinical development and expedite the path to commercialization
- Develop affordable, highly effective, and shorter HCV treatment regimens using Furaprevir as the anchor of cocktail therapy
- Utilize TaiGen’s NCE platform to develop a sustainable product pipeline
- Develop sales and marketing, manufacturing functions to become a fully integrated pharmaceutical company